The Longeveron investor presentation to be used at the conference is available at the “ Events & Presentations ” section of the Company’s website. About Longeveron Inc.

Climb Bio will begin trading on Nasdaq under the trading symbol "CLYM" effective October 3rd ...

Their leadership and guidance were instrumental in achieving our IPO, laying a strong foundation as OneMedNet entered the public markets. We thank them for their service and wish them the best in ...

Earlier in September, Femasys announced its strategic distribution partnerships for FemaSeed and FemVue in Spain. Comercial Medico Quirurigca, SA (CMQ) will distribute the products in northern Spain ...

As has recently been reported in the press, PharmAla has received numerous clinical trial inquiries and leads from key research organizations,” said Nicholas Kadysh, CEO, PharmAla Biotech. “We look ...

Invite to the Company’s R&D event on October 10, 2024 Medigene will host an R&D Event on Thursday, October 10, 2024, at 4.30 p.m. CEST / 10:30 a.m. ET. A live Q&A session will follow the formal ...

Yuhua Zhang, Ph.D., Principal Investigator at Doheny Eye Institute and Professor of Ophthalmology at the David Geffen School of Medicine, UCLA, will lead the development of the next generation of ...

IntelGenx Technologies Corp. (the “Company” or “IntelGenx”), a leading drug delivery company focused on the development and manufacturing of pharmaceutical films, announces that the Company and its ...

3rd Annual ROTH Healthcare Opportunities Conference Format: Panel discussion ( Opportunities and Challenges When Small Names Go After Blockbuster Indications) and one-on-one investor meetings Date: ...

As October marks World Menopause Awareness Month, ARC Fertility (ARC), a highly experienced national provider of innovative fertility, family-forming and women’s and men’s health benefits for ...

EnnoDC* (or “the Company”), a clinical-stage biotech company pioneering the development of first-in-class dendritic cell-targeting immunotherapies, today notes the publication of positive results from ...

NXC-201 is the only CAR-T therapy currently in development in AL Amyloidosis, mentioned in a review article entitled “Systemic Light Chain Amyloidosis” published in June, 2024 New England Journal of ...